Cost effectiveness of cephalosporin monotherapy and aminoglycoside/ureidopenicillin combination therapy: For the treatment of febrile episodes in neutropenic patients

PharmacoEconomics

Volumn 18, Issue 4, 2000, Pages 369-381

  Paladino, J A ^a   Fong, D A ^a   Forrest, A ^a   Ramphal, R ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEFEPIME; CEFTAZIDIME; GENTAMICIN; UREIDOPENICILLIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; RANDOMIZATION; RASH; RESOURCE MANAGEMENT; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; VOMITING;

EID: 0033779084     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200018040-00005     Document Type: Article

References (45)

1. Management of fever in patients with cancer and treatment-induced neutropenia
2. Empiric therapy for infections in the febrile, neutropenic, compromised host
3. Increasing incidence of Gram-positive sepsis in cancer patients
4. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: Clinical spectrum and risk factors
5. Enterobacter bacteremia: Clinical features and emergence of antibiotic resistance during therapy
6. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient
7. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients
8. Monotherapy for empiric treatment of fever in granulocytopenic cancer patients
9. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer: A multicenter randomized trial
10. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
11. The costs of treating febrile neutropenia in six UK hospitals
12. Cost considerations in therapy with myeloid growth factors
13. Health care outcomes case study: Febrile neutropenia
14. Cost-effectiveness comparison of cefepime and ceftazidime using decision analysis
15. Pharmacoeconomic comparison of cefepime versus ceftazidime in septic patients
16. New Drug Application 50-679. Maxipime® (cefepime HCl) for injection; empiric therapy in febrile neutropenic patient
17. Cefepime versus ceftazidime in the empiric therapy of febrile episodes in neutropenic patients
18. Open, randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients
19. Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients
20. Piperacillin-tazobactam versus cefepime as initial empiric antimicrobial therapy in febrile neutropenic patients: A prospective randomized pilot study
21. General guidelines for the evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients
22. The design, analysis and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient: Report of a consensus panel
23. Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia
24. Discounting in cost-effectiveness analysis of healthcare programmes
25. Methodological and conduct principles for pharmacoeconomic research
26. Evaluating the cost impact of intravenous antibiotic dosing frequencies
27. Comparison of seven methods of preparing and administering small-volume injections
28. Cost containment of reconstituted parenteral antibiotics: Personnel and supply costs associated with preparation, dispensing, and administration
29. A pharmacoeconomic model to evaluate antibiotic costs
30. Cost-effectiveness comparison of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients
31. Is it time to redefine the management of febrile neutropenia in cancer patients?
32. Clinical economics: A guide to the economic analysis of clinical practices
33. Guidelines for performing a pharmacoeconomic analysis
34. Bedside estimation of creatinine clearance: Which method is most accurate while least complex?
35. Fractional adjustment of predicted creatinine clearance in females
36. Clinical and economic considerations of empirical antibacterial therapy of febrile neutropenia in cancer
37. Neutropenia, fever and infections
38. Neutropenia and fever in patients receiving chemotherapy in a community teaching hospital: Results of a retrospective chart review
39. Evaluation of fever in the patient with cancer
40. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia
41. Cost effectiveness of abbreviating the duration of intravenous antibiotic therapy with oral fluoroquinolones